Cardiovascular and Metabolic Effects of <i>ANGPTL3</i> Antisense Oligonucleotides

2017574 citationsJournal Articlebronze Open Access

Authors

Mark J. Graham · Ionis Pharmaceuticals (United States)

Richard Lee · Ionis Pharmaceuticals (United States)

Teresa Brandt · Ionis Pharmaceuticals (United States)

Bruce L. Tai · Ionis Pharmaceuticals (United States)

Wuxia Fu · Ionis Pharmaceuticals (United States)

Raechel Peralta · Ionis Pharmaceuticals (United States)

Rosie Z. Yu

Abstract

Oligonucleotides targeting mouse Angptl3 retarded the progression of atherosclerosis and reduced levels of atherogenic lipoproteins in mice. Use of the same strategy to target human ANGPTL3 reduced levels of atherogenic lipoproteins in humans. (Funded by Ionis Pharmaceuticals; ClinicalTrials.gov number, NCT02709850 .).

Topics & Keywords

Lipid metabolism and disorders Cancer-related molecular mechanisms research Diabetes, Cardiovascular Risks, and Lipoproteins

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 377, Issue 3, pp. 222-232

DOI: 10.1056/nejmoa1701329

Field-Weighted Citation Impact: 44.60